Saying it wants a more robust data package for the FDA-stalled cancer drug cetuximab, Merck KGaA is delaying until the first half of next year the European regulatory filing, but now aims to include colorectal data as well as the originally planned head and neck cancer study results. (BioWorld Today) Read More
